• 생물정신의학
• /
• 제4권1호
• /
• pp.60-66
• /
• 1997

서울대학교병원 신경정신과에 입원하여 뇌자기공명영상촬영을 시행한 32명(남자 18명, 여자 12명)의 양극성장애환자를 대상으로 피질하 $T_2$ 강조-고신호광도의 임상적 변수에 관한 연구를 시행하여 다음과 같은 결과를 얻었다. 1) 32명의 환자중 피질하 고신호광도를 보인 환자의 수는 7명(21.8%)이었고, 8명의 40세 이상의 환자중에서는 5명(62%)이 고신호광도를 보였다. 2) 피질하 고신호광도를 보인 환자군이 그렇지 않은 군에 비해 통계적으로 유의한 수준으로 연령이 높았고(p<0.01), 연령과 정량화된 피질하 고신호광도 점수와의 상관분석에서도 유의한 양의 상관관계를 보였다(r=0.51, p<0.01). 3) 피질하 고신호광도를 보인 환자군에서 정신병적 증상의 빈도는 증가되고(p=0.06), 정동장애 가족력의 빈도는 감소한 경향을 보였다(p=0.01). 이상의 결과는 발병연령이 늦은 양극성장애 환자의 상당수에서 발견되는 피질하 고신호광도가, 유전적요인에 주로 영향을 받는 조기 발병군과는 다른 경과나 임상양상 등을 보이는 만발성 양극성장애 환자의 원인적 요소일 수 있다는 가설을 뒷받침해주는 소견이다.

• 생물정신의학
• /
• 제22권4호
• /
• pp.155-162
• /
• 2015

Objectives Second-generation antipsychotics (SGAs) are frequently used in the treatment of bipolar disorder. However, there is still no consensus on their risk of tardive movement syndromes especially for first-generation antipsychotics (FGAs)-naïve patients. This study aimed to investigate the prevalence and associated factors of SGAs-related tardive dyskinesia and tardive dystonia in patients with bipolar disorder, in a naturalistic out-patient clinical setting. Methods The authors assessed 78 non-elderly patients with bipolar (n = 71) or schizoaffective disorder (n = 7) who received SGAs with a combined use of mood stabilizers for more than three months without previous exposure to FGAs. Multiple direct assessments were performed and hospital records longer than one recent year describing any observed tardive movement symptoms were also reviewed. Results The prevalence rates of tardive dyskinesia and tardive dystonia were 7.7% and 6.4%, respectively. These patients were being treated with ziprasidone, risperidone, olanzapine, quetiapine, or paliperidone at the time of the onset of the movement symptoms. Tardive dyskinesia was mostly observed in the orolingual area, and tardive dystonia was most frequently detected in oromandibular area. A past history of acute dystonia was significantly associated with presence of both tardive movement syndromes. Conclusions Our findings suggest that SGAs-related tardive movement syndromes occur in a substantial portion of bipolar disorder patients. Acute dystonia, a reported risk factor of tardive movement syndromes in the era of FGAs is confirmed as a risk factor of both tardive dyskinesia and tardive dystonia that were induced-by SGAs.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제11권2호
• /
• pp.209-220
• /
• 2000

본 연구는 소아청소년에서의 우울증 및 조울증의 우울삽화에 대한 임상특성을 알아보고자 하였다. 1993년 3월 1일부터 1999년 10월 31일까지 OO대학교 어린이 병원 소아청소년 정신과에 입원하였던 34명의 우울증 환아와 17명의 조울증 우울삽화 환아를 대상으로 병록지 기록을 통해서 이들의 사회인구학적 특성, 진단적 분류, 입원시 주 증상 및 문제점, 증상의 빈도, 주산기 모 병력과 아동기 발달력, 공존 정신질환 및 신경 심리학적 검사, 가족의 임상적 특성, 가족 정신병리 및 가족 병력, 치료반응 등에 대하여 조사하였다. 1) 우울증에서 남자의 비율이 여성의 경우보다 높았으며, 조울증 우울삽화에서는 남녀의 비율이 비슷하였다. 2) 평균 발병 연령은 조울증 우울삽화에서 14.1세, 우울증에서 12.8세로 우울증에서 일찍 발병하는 양상을 나타냈으며, 입원 횟수에 있어서는 조울증 우울삽화에서 우울증에 비해서 많았다. 3) 조울증 우울삽화와 우울증 모두에서 식물증상의 호소가 신체증상보다 많았으며, 자살사고 증상은 우울증에서, 공격적인 증상은 조울증 우울삽화에서 많았고, 정신병적 증상에서는 망상은 우울증에서 환각은 조울증 우울삽화에서 많이 나타났다. 4) 두 집단 모두에서 불안장애가 가장 많이 동반되었으며, 신체형 장애, 정신지체, 인격장애 등이 동반되었다. 5) 조울증 우울삽화와 우울증 모두 높은 가족력을 보였고, 특히 우울증은 아동 학대력과 가족의 부적절한 양육과 관련성을 보였다. 성인에서 조울증과 우울증이 분명한 임상적 차이를 갖고있는 것처럼 소아에서도 조울증 우울삽화와 우울증은 발병연령, 신체증상 및 식물증상을 비롯한 임상증상의 차이, 공존질환 등에서 서로 다른 임상 양상을 나타내었다. 발병 위험이 통계적으로 유의하게 높다고 할 수 있었다. 2) 자신은 남들에게 인기도 없고, 따돌림을 당한다고 여기며 정신병적 증상을 가진 군(47명, 남자 31명, 여자 16명)은 단순히 정신병적 증상이 높은 군에 비해 불안 척도, 우울증 척도, 공격성, 대인 민감성, 학교 및 사회 적응 척도, 강박증상 척도, 공포불안 척도, 정신병적 증상, 신체적 증상 호소 등에서는 차이를 보이지 않았으나 자신이 따돌림을 받는다는 호소와 편집증은 더 높게 측정되었다. 그리고, 학교폭력 피해자 중에서 정신병적 증상이 유의하게 높게 측정되었고, 스스로 인기가 없다고 생각하는 대상들에서는, 불안 증상, 우울증, 공격성, 대인 예민성, 강박증상, 편집증, 신체 증상 호소 등이 정신병적 증상을 잘 설명해주었다 ($r^2$=0.93). 즉, 따돌림을 당한다고 호소한 집단은 정신병적 증상이 유의하게 높았고, 이를 통해 왕따 피해자는 정신병 발병 위험이 통계적으로 유의하게 높다고 할 수 있었다. 이를 통해서 따돌림과 같은 학교폭력 피해자가 불안증상, 우울증, 공격성, 대인 예민성, 강박증상, 편집증, 신체 증상 호소와 같은 문제를 보였을 경우에는 정신병적 증상 유무와 학교 적응, 집중력 장애, 사고개념 형성 장애 등을 확인하여 정신병의 진단을 고려해야 한다고 할 수 있다.탈트검사에서 기질성 뇌장애를 의심할만한 소견은 14명(63.5%)에서 보였다. 지능검사의 결과는 평균이상 IQ는 12명((54.5%), 지능지체 및 경계선 지능은 9명(41.0%)이었다. 5) 주 진단 및 공존진단：주 진단으로는 행실장애가 6명(27.3%), 경계선장애(borderline child) 5명(23.0%), 우울병 4명(18%)

• The Korean Journal of Physiology and Pharmacology
• /
• 제1권2호
• /
• pp.127-133
• /
• 1997

Lithium remains the most widely used therapeutic agent for bipolar affective disorder, particularly mania. Although many investigators have studied the effects of lithium on abnormalities in monoamine neuro-transmitter as a pathophysiological basis of affective disorder, the action mechanism of lithium ion remains still unknown. To explore the action mechanism of lithium in the brain, we examined the effects of lithium on the extrasynaptosomal concentrations of catecholamines and their metabolites. Synaptosomes were prepared from the rat forebrains and assays of catecholamines and metabolites were made using HPLC with an electrochemical detector. Lithium of 1mM decreased the extrasynaptosomal concentrations of NE from the control group of $3.07{\pm}1.19$ to the treated group of $0.00{\pm}0.00$ (ng/ml of synaptosomal suspension) but not that of DHPG. It can be suggested that lithium increases synaptosomal uptake of NE. Increased intraneuronal uptake of NE would decrease neurotransmission and extraneuronal metabolism of NE. Because increased brain NE metabolism and neurotransmission have been suggested as important components in the pathophysiology of bipolar affective disorder, especially mania, lithium-induced increase of intraneuronal NE uptake can be suspected as an action mechanism of therapeutic effect of lithium in manic patient, possibly in bipolar affective disorder.

• 동서간호학연구지
• /
• 제28권2호
• /
• pp.160-169
• /
• 2022

Purpose: This study was conducted to identify predictors related to aggressive behavior of patients with mental illness admitted to a closed psychiatric ward. Methods: This study adopted a retrospective design which analyzed the hospital medical records of 363 patients with mental illness admitted to the psychiatric closed ward of a university hospital in Seoul, Korea. The collected data were analyzed using SPSS IBM 20.0 and STATA 12.0 SE. ZIP (Zero-Inflated Poisson) and count data analysis were used for the factor influencing the occurrence and frequency of aggressive behavior. Results: The results of ZIP model showed that the factors influencing non-probability of aggressive behavior were anxiety, non-adherence, and frustration. In addition, the factors influencing frequency of aggressive behavior were bipolar disorder and personality disorder trait. Conclusion: We found that bipolar disorder, frustration, and non-adherence are more likely to increase the likelihood of aggressive behavior in patients with mental illness. In particular, patients diagnosed with bipolar disorder were 1.95 times more likely to engage in repetitive aggressive behavior compared to those without a diagnose. However, since the results were different form previous studies, further studies on the traits of anxiety and personality disorders are needed.

• 정신신체의학
• /
• 제22권2호
• /
• pp.112-120
• /
• 2014

연구목적 이 연구의 목적은 양극성 장애로 진단받은 정신과 외래 환자에서 야간 식이습관의 임상적 특성을 조사하는데 있다. 방 법 정신건강의학과 외래를 방문한 84명의 양극성 장애 환자를 대상으로 14개 항목의 야간 식이증후군 설문지(NEQ)를 자가 보고로 실시하였다. 이들의 인구학적, 임상적 특성을 조사하고 신체 질량 지수(BMI), 주관석 기분과 수면, 폭식과 체중에 관련된 삶의 질에 대한 평가를 Beck Depression Inventory(BDI), Binge Eating Scale(BES), Korean version of Obesity-related Quality of Life scale(KOQoL), Pittsburg Sleep Quality Index(PSQI) 등을 포함한 설문을 통해 얻었다. 결 과 양극성 장애 외래 환자 중 야간 식이증후군의 유병률은 14.3%(84명 중 12명)이었다. NES와 Non-NES군 사이에서는 경제적 상태와 동반되는 내과 질환을 제외한 성별, 나이, 교육 년 수, 결혼 및 직업 상태, 흡연, 음주 등의 인구사회학적 특성에서 양군간에 유의한 차이를 보이지는 않았다. 하지만, Non-NES 군에 비해 NES군에서 폭식이 많았고 비만으로 인한 삶의 질 저하가 나타났다. 결 론 이번 연구는 야간식이를 보이는 양극성 장애 외래환자의 임상적 특성을 처음으로 기술하였다. 비록 양극성 장애 외래 환자의NES군에서 뚜렷한 상관 관계를 보이는 특성이 많지는 않았지만, 상대적으로 NES 유병률이 높은 것으로 볼 때 임상에서 양극성 장애 환자 평가 시 비만 여부에 관계 없이 NES를 염두에 두어야 할 것이다.

• 신경정신의학
• /
• 제57권4호
• /
• pp.287-300
• /
• 2018

Of the different phases of bipolar disorder, bipolar depression is more prevailing and is more difficult to treat. However, there is a deficit in systemic research on the pharmacological treatment of acute bipolar depression. Therefore, consensuses on the pharmacological treatment strategies of acute bipolar depression has yet to be made. Currently, there are only three drugs approved by the Food and Drug Administration for acute bipolar depression : quetiapine, olanzapine-fluoxetine complex, and lurasidone. In clinical practice, other drugs such as mood stabilizers (lamotrigine, lithium, valproate) and/or the other atypical antipsychotics (aripiprazole, risperidone, ziprasidone) are frequently prescribed. There remains controversy on the use of antidepressants in bipolar depression. Here, we summarized the evidence of current pharmacological treatment options and reviewed treatment guidelines of acute bipolar depression from recently published studies.

• 우울조울병
• /
• 제16권3호
• /
• pp.129-133
• /
• 2018

Objectives : The fourth revision of Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was performed in 2018, to provide newer guidelines for clinicians. In this section, we examined expert opinions to facilitate clinical decisions relative to treating bipolar disorder with medical comorbidity. Methods : The survey was completed by the review committee, consisting of 61 experienced psychiatrists. This part of the survey constitutes treatment strategies, under major medical comorbidities. The executive committee analyzed results, and discussed the final production of algorithm. Results : Aripiprazole was the first-line medication for bipolar patients with metabolic syndrome, cardiovascular, hepatic, renal, and cerebrovascular comorbidities. Ziprasidone also was recommended as the first-line medication in case of metabolic syndrome. Lithium also was regarded as the first-line medication, in case of hepatic problems. Valproate also was considered as the first-line medication, in case of cerebrovascular problems. Conclusion : This study provided the most recent consensus among experts, for treatment of bipolar disorder with physical problems.

• Clinical Psychopharmacology and Neuroscience
• /
• 제16권4호
• /
• pp.376-382
• /
• 2018

We reviewed clinical studies investigating the pharmacological treatment of major depressive episodes (MDEs) with mixed features diagnosed according to the dimensional criteria (more than two or three [hypo]manic symptoms+principle depressive symptoms). We systematically reviewed published randomized controlled trials on the pharmacological treatment of MDEs with mixed features associated with mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). We searched the PubMed, Cochrane Library, and ClinicalTrials.gov databases through December 2017 with the following key word combinations linked with the word OR: (a) mixed or mixed state, mixed features, DMX, mixed depression; (b) depressive, major depressive, MDE, MDD, bipolar, bipolar depression; and (c) antidepressant, antipsychotic, mood stabilizer, anticonvulsant, treatment, medication, algorithm, guideline, pharmacological. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We found few randomized trials on pharmacological treatments for MDEs with mixed features. Of the 36 articles assessed for eligibility, 11 investigated MDEs with mixed features in mood disorders: six assessed the efficacy of antipsychotic drugs (lurasidone and ziprasidone) in the acute phase of MDD with mixed features, although four of these were post hoc analyses based on large randomized controlled trials. Four studies compared antipsychotic drugs (olanzapine, lurasidone, and ziprasidone) with placebo, and one study assessed the efficacy of combination therapy (olanzapine+fluoxetine) in the acute phase of BD with mixed features. Pharmacological treatments for MDEs with mixed features have focused on antipsychotics, although evidence of their efficacy is lacking. Additional well-designed clinical trials are needed.

• 생물정신의학
• /
• 제23권4호
• /
• pp.185-192
• /
• 2016

Objectives Treatment response of bipolar disorders (BDs) to long-term mood stabilizers maintenance has not been well explored because of complicated clinical and treatment courses. This study aims at investigating long-term clinical response of BDs to lithium and/or valproate in a naturalistic setting of a tertiary-care university-affiliated hospital. Methods Subjects were 65 patients with bipolar I (BD-I) disorders who had been treated with lithium and/or valproate for more than two years at single bipolar disorder clinic. Long-term response to the best treatment based on treatment algorithms and the current clinical standard of care was retrospectively evaluated using the Alda Scale and the Clinical Global Impression Scale for use in bi-polar illness (CGI-BP). Patients were classified into full responder and partial/non responder groups based on the total score of the Alda Scale with the cut-off score generated from the frequentist mixture analysis of the authors' previous study. Results The mean duration of treatment with the index medication was 69.2 months. Baseline demographic and clinical characteristics were not different among three mood stabilizer groups (valproate, lithium, and combination groups). Twenty-one subjects were classified into full responder group (32.3%). Treatment response assessed by the Alda Scale and CGI-BP scores was not different between lithium and valproate groups. The Alda Scale scores were well correlated with the CGI-BP scores (p < 0.05). Conclusions One third of the patients showed a full response to the long-term lithium and/or valproate treatment in BD-I. The degree of response was similar between lithium and valproate groups.